Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE
Revolution Medicines (RVMD) is in focus after the FDA approved RASONQUE, an oral RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma following prior systemic therapy or for those unsuitable for multiagent regimens.
Revolution Medicines’ share price is around US$205.57 after a slight pullback over the past week. The 30 day share price return of 9.62% and 90 day share price return of 35.86% sit against a year to date share price return of 160.15%, while the 1 year total shareholder return of 441.40% points to strong longer term momentum as investors reassess growth prospects and risk around the newly approved RASONQUE therapy.
Scan for other oncology stocks with fresh catalysts and strong price momentum by reviewing the 19 high quality undiscovered gems alongside Revolution Medicines after this RASONQUE approval shift.
For Revolution Medicines, the recent surge around RASONQUE appears tied to a major step in the underlying RAS(ON) franchise rather than a simple mood swing. How does that backdrop compare with today’s valuation?
Most Popular Narrative: 7.4% Undervalued
Revolution Medicines closed at $205.57, while the most followed narrative sets fair value at about $221.90. This frames today’s price against an aggressive RAS franchise build out.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Want to understand why this RAS story supports a higher fair value for Revolution Medicines? The narrative leans on steep revenue build, margin uplift and a premium future earnings multiple. Curious which specific forecasts need to land for that view to hold.
Result: Fair Value of $221.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Revolution Medicines narrative can still break if heavy R&D spending keeps losses elevated for longer or if key Phase 3 RAS trials disappoint regulators.
Find out about the key risks to this Revolution Medicines narrative.
Another View on Revolution Medicines Valuation
The fair value of $221.90 for Revolution Medicines comes from a narrative style model that leans heavily on long term growth and margins. Looking at a more grounded yardstick, the current P/B ratio of 16.9x versus 9.9x for peers and 2.5x for the wider US Biotechs group suggests the stock is expensive on this measure. That kind of premium can reward you if the RAS story keeps delivering, but it also raises the question of how much disappointment the share price can absorb.
To see what the numbers say about this price, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Given this mix of enthusiasm and concern around Revolution Medicines, it makes sense to review the underlying data yourself and form an independent view. To weigh up both sides of the argument, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Revolution Medicines?
If you only focus on Revolution Medicines, you could miss other opportunities that fit your goals. Use the Simply Wall Street Screener to surface ideas that match your risk, income and growth preferences.
- Identify companies that trade below their assessed value and still show solid fundamentals by reviewing the 45 high quality undervalued stocks.
- Strengthen your income stream by targeting businesses that prioritize cash returns to shareholders through the 12 dividend fortresses.
- Protect your capital by focusing on companies with comparatively steadier risk profiles using the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com